Abstract CT017: FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed
Pasi A. Jänne(Harvard University), David Planchard(Université Paris-Saclay), Sang‐We Kim(Ulsan College), Tsung‐Ying Yang(National Chung Hsing University), Ryan J. Hartmaier(AstraZeneca (United States)), James Chih‐Hsin Yang(National Taiwan University Hospital), Aleksandra Markovets(AstraZeneca (United States)), Preetida J. Bhetariya(AstraZeneca (United States)), Chee Khoon Lee(The University of Sydney), Dana Ghiorghiu(AstraZeneca (United Kingdom)), Jacqulyne Robichaux(Houston Public Library), Shunichi Sugawara(Sendai Kousei Hospital), Tae Min Kim(Seoul National University Hospital), Noriko Yanagitani(The Cancer Institute Hospital), Lynne Poole(AstraZeneca (United Kingdom)), Kunihiko Kobayashi(Saitama International Medical Center)
Cited by 25
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k